Trivalent inactivated influenza virus vaccine given to two-month-old children: an off-season pilot study.

Background: Although children less than 6 months of age have the highest risk for hospitalization related to influenza infection, influenza vaccine is not approved for these children.

Methods: In an open-label, off-season study, healthy 6 to 12 week and 6-month-old children received 2 doses of the 2004 to 2005 trivalent inactivated influenza vaccine (TIV) administered 1 month apart along with other routine pediatric vaccines. Safety was assessed by parental diaries (n = 393).

Safety and immunogenicity of trivalent inactivated influenza vaccine in infants: a randomized double-blind placebo-controlled study.

Background: Infants less than 6 months of age are at high risk for influenza disease and influenza-related complications, but no vaccine is licensed for this population.

Methods: A double-blind, randomized, placebo-controlled trial was conducted in 1375 healthy US infants 6 to 12 weeks of age. Subjects received 2 doses of trivalent inactivated influenza vaccine (TIV, Fluzone, sanofi pasteur; N = 915) or placebo (N = 460) 1 month apart in combination with indicated concomitant vaccines.

Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects.

To improve immune responses to influenza vaccine, a trivalent inactivated vaccine containing 60 microg of the HA of each component (A/H3N2, A/H1N1, B) was compared to a licensed vaccine containing 15 microg of the HA of each. More local and systemic reactions were reported by subjects given the high dosage but only local pain and myalgias were significantly increased. The high dosage vaccine induced a higher frequency of serum antibody increases (> or =4-fold) in both hemagglutination-inhibiting (HAI) and neutralization tests for all three vaccine viruses in the total group as well as subjects vaccinated and those not vaccinated the previous year.

Immunogenicity and safety of inactivated influenza virus vaccine in young children in 2003-2004.

This study assessed the safety and immunogenicity of a pediatric formulation of the 2003-2004 inactivated, trivalent, split virion influenza vaccine, administered in a 2-dose schedule in healthy children ages 6-36 months, of whom 94% had protective titers (> or =1/40) to at least 1 antigen. The 2003-2004 split virion influenza vaccine was safe and immunogenic in young children.

Inactivated influenza virus vaccines in children.

Healthy children aged < or =2 years have hospitalization rates during influenza periods 12 times those of older children and comparable to rates in the elderly population. In 2003, killed influenza vaccines were "recommended" for children with high-risk conditions and were "encouraged" for children aged 6-23 months. Studies involving several thousand children show that split-virus vaccines are safe and immunogenic in healthy children aged > or =6 months and in high-risk children.

Maritime health: a case for preventing influenza on the high seas.

For decades cruise ships have been recognized as foci for diarrheal illness. More recently influenza has been added to the list of diseases for which people on cruise ships are at risk. Influenza is a business risk involving cruise ship operating and litigation costs and travelers' loss in value.

Immediate hypersensitivity reactions after use of tuberculin skin testing.

This report describes the frequency and characteristics of serious or life-threatening hypersensitivity reactions to the tuberculin skin test over an 11-year period through November 2000. There were 24 reports and no deaths, indicating that such reactions are rare (0.08 reported reactions per million doses of tuberculin).